NASDAQ · DXCM
Healthcare · Medical - Devices
$90.82
Down-$1.02 (-1.12%)
Updated Aug 31, 2026, 1:54 PM
SID Score
7.3/10
Composite research score
Smart Money
59/100
Neutral
Price performance
1M range · 20 trading sessions · Daily adjusted prices
DXCM closed at $90.82 after 20 trading sessions, up 4.02% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 28, 2026 | $89.805 | $90.84 | $88.825 | $90.82 | 2.55M |
| Aug 27, 2026 | $88.37 | $90.43 | $87.60 | $89.29 | 3.03M |
| Aug 26, 2026 | $88.17 | $89.76 | $87.51 | $88.96 | 3.82M |
| Aug 25, 2026 | $90.731 | $91.14 | $88.78 | $89.16 | 4.11M |
| Aug 24, 2026 | $92.30 | $92.59 | $91.03 | $91.06 | 4.45M |
| Aug 21, 2026 | $89.605 | $92.56 | $89.1964 | $92.34 | 3.48M |
| Aug 20, 2026 | $89.42 | $91.385 | $89.275 | $90.22 | 5.16M |
| Aug 19, 2026 | $90.30 | $91.915 | $89.235 | $89.88 | 8.67M |
| Aug 18, 2026 | $89.49 | $91.4999 | $88.98 | $89.60 | 3.36M |
| Aug 17, 2026 | $89.34 | $89.90 | $88.145 | $88.76 | 4.05M |
| Aug 14, 2026 | $91.96 | $91.96 | $89.42 | $89.75 | 3.86M |
| Aug 13, 2026 | $90.82 | $91.62 | $90.15 | $91.48 | 4.69M |
| Aug 12, 2026 | $89.04 | $91.04 | $88.265 | $90.80 | 5.4M |
| Aug 11, 2026 | $87.59 | $89.555 | $87.055 | $89.53 | 5.97M |
| Aug 10, 2026 | $84.81 | $88.175 | $84.525 | $87.65 | 7.83M |
| Aug 7, 2026 | $82.49 | $85.055 | $82.09 | $84.75 | 4.63M |
| Aug 6, 2026 | $82.91 | $83.69 | $82.4699 | $83.02 | 3.87M |
| Aug 5, 2026 | $86.47 | $86.47 | $82.30 | $82.66 | 6.01M |
| Aug 4, 2026 | $87.14 | $87.85 | $86.21 | $86.94 | 6.12M |
| Aug 3, 2026 | $85.25 | $87.63 | $83.50 | $87.31 | 9.19M |
The latest Smart Investors Daily articles mentioning DXCM.
DXCM research
Company profile and research snapshot.
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 4, 2026 | Argus Research | Buy | — |
| Aug 3, 2026 | Canaccord Genuity | Buy | — |
| Jul 31, 2026 | BTIG | Buy | — |
| Jul 31, 2026 | Citigroup | Buy | — |
| Jul 31, 2026 | Piper Sandler | Overweight | — |
No generated briefing is available yet.
ChartMill · Aug 27, 2026
Discover why DexCom (DXCM) fits the Affordable Growth screen, balancing strong earnings growth with reasonable valuation and solid financial health.
ChartMill · Aug 20, 2026
Dexcom (DXCM) passes strong growth & technical screens with high scores, solid fundamentals, and a bull flag breakout setup.
Yahoo · Aug 19, 2026
IDEXX pairs resilient diagnostics growth, margin gains and expanding innovation with a premium valuation that supports a hold-or-wait stance.
Yahoo · Aug 18, 2026
DexCom stock has gained 33.4% year to date, yet the valuation picture is mixed, with the intrinsic value estimate from a Discounted Cash Flow (DCF) model pointing to meaningful upside while the broader checks lean less generous. For investors, the question is how to weigh a DCF signal that suggests the shares trade at a discount against a low overall value score. Year to date, DexCom is up 33.4%, which puts more pressure on the current price to be supported by future cash flows. Expectations...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning DXCM.
